<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023399</url>
  </required_header>
  <id_info>
    <org_study_id>ARAMF_L_04314</org_study_id>
    <nct_id>NCT01023399</nct_id>
  </id_info>
  <brief_title>Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire</brief_title>
  <official_title>A Nested Open Labeled Study to Compare the Effectiveness and Safety of a Fixed-dose Combination of Artesunate Plus Amodiaquine (ASAQ Winthrop®) in the Unsupervised Treatment of Uncomplicated Plasmodium Falciparum Malaria Attacks in Two Patient Groups Enrolled at Two Year-intervals in a Pilot District of Côte d'Ivoire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the non-inferiority of Polymerase Chain
      Reaction (PCR)-adjusted adequate clinical and parasitological response to artesunate plus
      amodiaquine at Day 28 in two groups of patients treated at the beginning of an artesunate
      plus amodiaquine implementation program and 24 months later.

      The secondary objectives are Clinical and biological tolerability Evolution of gametocyte
      carriage Proportion of patients without fever at Day 3 Proportion of patients without
      parasite at Day 3 Treatment compliance Impact of implementation on anemia Measure of parasite
      sensibility to amodiaquine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polymerase chain reaction (PCR)-corrected and uncorrected clinical and parasitological cure rate (ACPR)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients without fever</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without parasite</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of gametocytes</measure>
    <time_frame>Day 3, Day 7, Day 14, Day 21 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of in vitro resistance rate</measure>
    <time_frame>Day 3, Day 7, Day 14, Day 21 and Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Artesunate + Amodiaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral fixed combination of artesunate (AS) and amodiaquine (AQ)
Once daily, dose according to age
Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)
Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)
Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)
Adults: &gt;= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)
3 day-treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate + Amodiaquine</intervention_name>
    <description>Artesunate + Amodiaquine fixed dose combination</description>
    <arm_group_label>Artesunate + Amodiaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight &gt;=5kg

          -  Plasmodium falciparum infection with parasite density &gt; 2000/µL

          -  Fever or history of fever

          -  Able to be treated by oral route

          -  No signs of severe malaria

          -  No known allergy to study drugs

          -  No other severe illnesses or underlying diseases

          -  No known pregnancy or negative urinary pregnancy test for women of child bearing age

          -  No participation in another ongoing clinical study

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 1</name>
      <address>
        <city>Agboville district</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

